Literature DB >> 7117753

Enhanced tumor metastases in rats following cryosurgery of primary tumor.

T Yamashita, K Hayakawa, M Hosokawa, T Kodama, N Inoue, K Tomita, H Kobayashi.   

Abstract

The incidence of tumor metastases was studied in WKA/Hok rats after cryosurgery and surgical excision of primary tumors. When rats with syngeneic fibrosarcoma, KMT-17, were treated by cryosurgery 5 days after transplantation of the tumor, 15 out of 31 rats (48.4%) died with tumor metastases. In contrast only 4 out of 34 (11.8%) died with tumor metastasis after surgical excision. Because tumor cells either in the regional lymph nodes or in the peripheral blood were already detectable in about half of the rats treated by either cryosurgery or surgical excision, mechanical and physical control of enhanced metastasis by cryosurgery is ruled out. The development of anti-tumor immunity was delayed in the rats treated by cryosurgery as compared with that in rats treated by surgical excision. This was investigated by means of Winn's assay. A marked reduction of tumor metastasis was seen after the surgical removal of cryonecrotized tumor tissue, while implantations of cryonecrotized tumor tissue into the rats treated by surgical excision resulted in an increment of metastasis. The mechanism of the enhanced metastasis observed in this experimental investigation is discussed from an immunological point of view.

Entities:  

Mesh:

Year:  1982        PMID: 7117753

Source DB:  PubMed          Journal:  Gan        ISSN: 0016-450X


  10 in total

Review 1.  Thermal ablation of tumours: biological mechanisms and advances in therapy.

Authors:  Katrina F Chu; Damian E Dupuy
Journal:  Nat Rev Cancer       Date:  2014-03       Impact factor: 60.716

2.  Potent induction of tumor immunity by combining tumor cryoablation with anti-CTLA-4 therapy.

Authors:  Rebecca Waitz; Stephen B Solomon; Elena N Petre; Anne E Trumble; Marcella Fassò; Larry Norton; James P Allison
Journal:  Cancer Res       Date:  2011-11-22       Impact factor: 12.701

Review 3.  Harnessing the immunomodulatory effect of thermal and non-thermal ablative therapies for cancer treatment.

Authors:  Christopher Bastianpillai; Neophytos Petrides; Taimur Shah; Stephanie Guillaumier; Hashim U Ahmed; Manit Arya
Journal:  Tumour Biol       Date:  2015-09-30

4.  Cryotherapy with concurrent CpG oligonucleotide treatment controls local tumor recurrence and modulates HER2/neu immunity.

Authors:  Jesse J Veenstra; Heather M Gibson; Peter J Littrup; Joyce D Reyes; Michael L Cher; Akira Takashima; Wei-Zen Wei
Journal:  Cancer Res       Date:  2014-08-04       Impact factor: 12.701

5.  Cyclophosphamide unmasks an antimetastatic effect of local tumor cryoablation.

Authors:  Moshe Yair Levy; Abhinav Sidana; Wasim H Chowdhury; Steven B Solomon; Charles G Drake; Ronald Rodriguez; Ephraim J Fuchs
Journal:  J Pharmacol Exp Ther       Date:  2009-04-30       Impact factor: 4.030

6.  Comparison of excision versus cryosurgery of an HSV-2-induced fibrosarcoma. I. Survival, extent of metastatic disease and host immunocompetence following surgery.

Authors:  M G Wing; J R Goepel; G Jacob; R C Rees; K Rogers
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

7.  Characterisation of suppressor cells generated following cryosurgery of an HSV-2-induced fibrosarcoma.

Authors:  M G Wing; K Rogers; G Jacob; R C Rees
Journal:  Cancer Immunol Immunother       Date:  1988       Impact factor: 6.968

Review 8.  More than just tumor destruction: immunomodulation by thermal ablation of cancer.

Authors:  Sebastian P Haen; Philippe L Pereira; Helmut R Salih; Hans-Georg Rammensee; Cécile Gouttefangeas
Journal:  Clin Dev Immunol       Date:  2011-12-29

Review 9.  Thermal Ablative Therapies and Immune Checkpoint Modulation: Can Locoregional Approaches Effect a Systemic Response?

Authors:  Amol Mehta; Rahmi Oklu; Rahul A Sheth
Journal:  Gastroenterol Res Pract       Date:  2016-03-08       Impact factor: 2.260

Review 10.  Cytoreductive treatment strategies for de novo metastatic prostate cancer.

Authors:  Martin J Connor; Taimur T Shah; Gail Horan; Charlotte L Bevan; Mathias Winkler; Hashim U Ahmed
Journal:  Nat Rev Clin Oncol       Date:  2019-11-11       Impact factor: 66.675

  10 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.